The relative cost effectiveness of insulin glargine versus NPH insulin using UK real life data in type I diabetes mellitus

被引：0
|
作者：
McEwan, P.
Mehin, N.
Tetlow, A. P.
Sharplin, P.
机构：
[1] Univ Cardiff Wales, Cardiff, S Glam, Wales
[2] Sanofi Aventis, Paris, France
[3] CRC, Cardiff, S Glam, Wales
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)68736-0
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A65 / A65
页数：1
相关论文
共 50 条
  • [41] Cost Savings in Type 2 Diabetes with Insulin Glargine Compared with Insulin Detemir in the UK
    Evans, Marc
    Owens, David
    Carroll, Dawn
    Keech, Martin
    [J]. DIABETES, 2009, 58 : A517 - A517
  • [42] Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting
    Marc Evans
    Roopa Mehta
    Jens Gundgaard
    Barrie Chubb
    [J]. Diabetes Therapy, 2018, 9 : 1919 - 1930
  • [43] Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting
    Evans, Marc
    Mehta, Roopa
    Gundgaard, Jens
    Chubb, Barrie
    [J]. DIABETES THERAPY, 2018, 9 (05) : 1919 - 1930
  • [44] Glargine versus NPH insulin in cystic fibrosis related diabetes
    Grover, Patricia
    Thomas, William
    Moran, Antoinette
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2008, 7 (02) : 134 - 136
  • [45] Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China
    James L. Palmer
    Amélie Beaudet
    Jeremy White
    Juliette Plun-Favreau
    Jayne Smith-Palmer
    [J]. Advances in Therapy, 2010, 27 : 814 - 827
  • [46] Cost-Effectiveness of Biphasic Insulin Aspart versus Insulin Glargine in Patients with Type 2 Diabetes in China
    Palmer, James L.
    Beaudet, Amelie
    White, Jeremy
    Plun-Favreau, Juliette
    Smith-Palmer, Jayne
    [J]. ADVANCES IN THERAPY, 2010, 27 (11) : 814 - 827
  • [47] Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece
    Tzanetakos, Charalampos
    Bargiota, Alexandra
    Kourlaba, Georgia
    Gourzoulidis, George
    Maniadakis, Nikos
    [J]. CLINICAL DRUG INVESTIGATION, 2018, 38 (01) : 67 - 77
  • [48] COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
    Xu, J.
    Lan, K.
    Wang, J.
    [J]. VALUE IN HEALTH, 2020, 23 : S111 - S111
  • [49] Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Insulin-naive Chinese Patients With Type 2 Diabetes
    Cheng, Huafeng
    Wan, Xu
    Ma, Jing
    Wu, Bin
    [J]. CLINICAL THERAPEUTICS, 2019, 41 (03) : 445 - 455
  • [50] Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece
    Charalampos Tzanetakos
    Alexandra Bargiota
    Georgia Kourlaba
    George Gourzoulidis
    Nikos Maniadakis
    [J]. Clinical Drug Investigation, 2018, 38 : 67 - 77
12345